Bio-Rad Laboratories (NYSE:BIO.B) Announces Quarterly Earnings Results

Bio-Rad Laboratories (NYSE:BIO.B) issued its quarterly earnings data on Thursday. The company reported $2.54 EPS for the quarter, Zacks reports. The business had revenue of $585.40 million for the quarter. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%.

Bio-Rad Laboratories Price Performance

NYSE:BIO.B opened at $234.41 on Friday. The stock has a 50 day moving average price of $251.20 and a 200 day moving average price of $306.24. The stock has a market cap of $6.57 billion, a PE ratio of -3.60 and a beta of 0.94. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48. Bio-Rad Laboratories has a one year low of $225.29 and a one year high of $359.22.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.